Sandeep Seth

Sandeep Seth

Auto-generated profile, based on publicly available information

Sandeep Seth

Department of Cardiology, All India Institute of Medical Science, New Delhi, India

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Phytomedicine
Verified
Journal Article
Closed access
SMSubir K Maulik
Subir K Maulik
VWVinu Wilson
Vinu Wilson
SSSandeep Seth
Sandeep Seth
BBBalram Bhargava
Balram Bhargava
PDPamila Dua
Pamila Dua
CKChandra K Katiyar
Chandra K Katiyar

1 June 2013 in Journal of Nuclear Cardiology
Verified
Journal Article
Closed access
PDF file
HSHarmandeep Singh
Harmandeep Singh
ASAbhinav Singhal
Abhinav Singhal
PSPunit Sharma
Punit Sharma
CPChetan D. Patel
Chetan D. Patel
SSSandeep Seth
Sandeep Seth
AMArun Malhotra
Arun Malhotra

1 April 2011 in American Journal of Cardiovascular Drugs
Verified
Journal Article
Closed access
PDF file
SRSivasubramanian Ramakrishnan
Sivasubramanian Ramakrishnan
RTRajendra Thangjam
Rajendra Thangjam
ARAMBUJ ROY
AMBUJ ROY
SSSandeep Singh
Sandeep Singh
LRLakshmy Ramakrishnan
Lakshmy Ramakrishnan
BBBalram Bhargava
Balram Bhargava

22 May 2021 in The Egyptian Heart Journal
Verified
Journal Article
Open access
PDF file
SDSoumi Das
Soumi Das
SSSandeep Seth
Sandeep Seth
Background: Dilated cardiomyopathy (DCM) is a disease of the heart muscle characterized by ventricular dilation and a left ventricular ejection fraction of less than 40%. Unlike hypertrophic cardiomyopathy (HCM) and arrhythmogenic right ventricular cardiomyopathy (ARVC), DCM-causing mutations are present in a large number of genes. In the present study, we report a case of the early age of onset of DCM associated with a pathogenic variant in the RBM20 gene in a patient from India. Case presentation: A 19-year-old Indian male diagnosed with DCM was suggested for heart transplantation. His ECG showed LBBB and echocardiography showed an ejection fraction of 14%. He had a sudden cardiac death. A detailed family history revealed it to be a case of familial DCM. Genetic screening identified the c.1900C>T variant in the RBM20 gene which led to a missense variant of amino acid 634 (p.Arg634Trp). Conclusion: To the best of our knowledge, the variant p.Arg634Trp has been earlier reported in the Western population, but this is the first case of p.Arg634Trp in an Indian patient. The variant has been reported to be pathogenic at an early age of onset; therefore, close clinical follow-up should be done for the family members caring for the variant.

1 January 2024 in Florence Nightingale Journal of Nursing
Verified
Journal Article
Open access
PDPriyanshi Dixit
Priyanshi Dixit
SGSandhya Gupta
Sandhya Gupta
SSSandeep Seth
Sandeep Seth
SSSujata Satapathy
Sujata Satapathy
YDYumnam Surbala Devi
Yumnam Surbala Devi
AIM: The present study was conducted to explore the lived-in experiences of post-heart transplant patients. METHODS: This study with a hermeneutic phenomenological approach was conducted on 23 heart transplant recipients in a tertiary hospital, AIIMS, New Delhi, India, from August to December 2020. Participants were selected through total enumerative sampling. Data were collected through semistructured interviews. The data analysis was performed according to Smith’s interpretative phenomenological approach. COREQ criteria for reporting qualitative research were used. RESULTS: In this study, reported experiences were divided into eight themes: (i) sickness, (ii) psychological changes, (iii) waiting for the heart, (iv) doubting survival, (v) interconnectedness between recipient and donor, (vi) living with vigilance, (vii) living with a transplanted heart, and (viii) God’s significant role. Transplant Day has arrived as a ray of hope in the recipient’s life. However, life after a transplant requires strict adherence to the medical regime, programmed follow-up care, dietary restrictions, physical limitations, and family support. Uncertainty and unpredictability about the future were important concepts in this research. CONCLUSION: The study suggests heart transplant (HT) recipients need mental strength and specialized, focused psychosocial intervention besides preoperative and postoperative care during the transplant process. Cite this article as: Dixit, P., Gupta, S., Seth, S., Satapathy, S., & Surbala Devi, Y. (2024). A hermeneutic phenomenological study on experiences of patients post heart transplantation. Florence Nightingale Journal of Nursing, 32(1), 51-57.

30 December 2025 in Cardiology and Therapy
Verified
Journal Article
Open access
PDF file
JAJabir Abdulakutty
Jabir Abdulakutty
AAAtul Abhyankar
Atul Abhyankar
SSSandeep Seth
Sandeep Seth
KSKamal Sharma
Kamal Sharma
RARakesh Kumar Aggarwal
Rakesh Kumar Aggarwal
AGAshish Gawde
Ashish Gawde
Introduction Patients with heart failure with reduced ejection fraction (HFrEF) experience higher rates of in-hospital and all-cause mortality. On the basis of the VERINA trial, vericiguat is indicated for patients who have had a worsening heart failure (WHF) event despite optimal heart failure (HF) therapy, or for those with tolerability concerns. Methods This multicenter, prospective, single-arm, non-randomized, real-world, descriptive study assessed the efficacy and safety of vericiguat in Indian patients aged ≥18 years with chronic HFrEF who were vericiguat-naïve and started treatment as per the local label. This analysis is based on interim data and the final results may differ. The main endpoint was a composite of cardiovascular (CV) death or first HF hospitalization. Secondary endpoints included each component of the primary outcome, all-cause death, and safety. Dose-titration parameters, including time to reach and duration at various dose levels, were also assessed. Results A total of 205 patients were enrolled (58.0 ± 13.27 years; 73.7% male; 34.1% aged ≥ 65 years, baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP) 2490.1 pg/mL). Left ventricular ejection fraction (LVEF) < 30% was observed in 48.8% patients, 24.9% were in New York Heart Association (NYHA) class III. WHF events included recent HF hospitalization within < 7 days (10.7%) or 7 days–3 months (30.2%). Common background therapies included β-blockers (84.9%), mineralocorticoids receptor antagonist (MRAs) (80.5%), sodium-glucose cotransporter 2 (SGLT2) inhibitors (75.6%), and angiotensin receptor-neprilysin inhibitor (ARNI) (52.7%), with 66.3% receiving triple HF therapy. Vericiguat target dose (10 mg) was achieved by 91.1% of patients. Conclusion This study enrolled high-risk patients with recent decompensation event consistent with the VICTORIA trial. The usage of standard of care (SoC) was as per current clinical practice in HF; VERINA enrolled 52.7% on ARNI compared to 14.5% in VICTORIA and 75.6% on SGLT2i compared to 2% in VICTORIA. Safety data did not reveal any new safety signals or adverse trends in the interim analysis. Trial Registration Clinical Trials Registry of India (CTRI/2022/11/047636).